EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of a Case of T-Lymphoblastic Lymphoma with Unrelated Cord Blood Stem Cell Transplantation



Treatment of a Case of T-Lymphoblastic Lymphoma with Unrelated Cord Blood Stem Cell Transplantation



Blood 100(11): Abstract No 5102, November 16



One pediatric T-lymphoblastic lymphoma (T-LBL) has been transplanted with unrelated cord blood progenitor cells and has been disease-free survival for two years. She is an 8-year-pupil. She had pain in her right eye with a red mass in her eyelid on May 1998. A mass increasing in diameter and was of 20x20 mm appeared in her right parotid gland on Jun 1999. Pathological test showed T-LBL. There were 6.0% of lymphoblastic cells in her bone marrow and the blasts in her center nervous system fluid after the two courses of NHL-type chemotherapy. She had CR after receiving ALL-type regimen (DNR, VCR, L-ASP, and Pred). Then she received 4 times of intrathecal injection (DXM, MTX, and Ara-C) and intensive chemotherapy with DXM and CY, admycin, Vindesine and Cytarabine. He then received unrelated, ABO major and minor incompatibility, HLA partially matched cord blood cell transplantation. The donor was from Shanghai Blood Bank. The ABO blood group of donor is O .The receipt's was A. HLA type of the donor and receipt is HLA-A2/-, HLA-B 46/60, HLA-DR 9/12, and HLA-A 2/33, HLA-B 46/60, HLA-DR 9/12, respectively. The condition regimen consisted of total body irradiation (400cGy, -6d, -5d) and CY (60mg/kg, -4d, -3d), VP-16 (18mg/kg, -4dapprx -2d). The cord blood cells transfused on July 9, 2000. The dose of mononuclear cells was 1.538x109 included CD34 positive cells was 0.833%. The dose of CFU-GM colony was >100/1.0x105, BFU-E was 15/1.0x105. The regimen of prophylactic GVHD consisted with the combination of ATG (2.5 mg/kg, -4dapprx-2d), CsA (2mg/kg, -1apprx) and MTX (10mg, +1, +3, +6, +11d). His WBC decreased to 0 at +3d and had remained 0 for 13d after CBT. The red rash skin and white piebald skin appeared in her neck and around her ear at +21d and had disappeared after treating with methylprednisolone (60mg/d daily) for seven days. She had fungi and several bacterial infections in oral cavity and gastrointestinal tract. Her hemapoietic recovery was at +25d. The HLA phenotype changed to O type at +45d. She has moved out from the air laminar flow room at +53d. Her blood group changed from O to A at +57d. The gene map test showed donor's picture. She has had disease-free survival for two years. She is regular normal live and study under our following-up now. She has been to his school for 1 and half year. T-LBL cells is same as acute T-ALL cells to tend to infiltrate some organs such as bone marrow, CNS, spleen that results in relapse. This disease also can be called as T-lymphoblastic lymphoma/leukemia. Some pathologist thought T-LBL and T-ALL were a disease but two names. The patient with T-LBL had lymphoblastic cells infiltration in bone marrow and CNS. Clinicians think the disease should be treated ALL-type chemotherapy. BFM Group reported LBL patients have 80%-90% long-term disease-free survival. Some refractory patients need progenitor cells transplantation. Pre-transplantation therapy is very important for the waiting patients. So they should give ALL-type regimen as pre-transplantation therapy. The patient underwent CBT showed successful graft. His blood group, HLA-type and gene map has changed to donor's picture. Although she has disease-free survival for two years, she still need under our follow-up.

(PDF 0-2 workdays service: $29.90)

Accession: 035980661

Download citation: RISBibTeXText



Related references

Successful treatment of minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia with imatinib followed by reduced-intensity unrelated cord blood transplantation after allogeneic peripheral blood stem cell transplantation. International Journal of Hematology 84(2): 170-173, 2006

Reduced intensity stem cell cell transplantation from unrelated umbilical cord blood for the treatment of adult T-cell leukemia/lymphoma A feasibility study with six patients. Blood. 102(11): 480b, Ember 16, 2003

Successful treatment of refractory advanced nasal NK/T cell lymphoma with unrelated cord blood stem cell transplantation incorporating focal irradiation. International Journal of Hematology 91(1): 107-111, 2010

Successful treatment of agammaglobulinemia by HLA-mismatched unrelated cord blood stem cell transplantation--the first case report. Zhonghua Xue Ye Xue Za Zhi 26(7): 401-403, 2005

Treatment of two case childhood acute lymphoblastic leukemia by HLA-mismatched unrelated umbilical cord blood transplantation. Zhonghua Xue Ye Xue Za Zhi 23(4): 198-201, 2002

Successful treatment of one case acute lymphoblastic leukemia by HLA-mismatched unrelated umbilical cord blood transplantation. Zhonghua Er Ke Za Zhi 42(7): 552-552, 2004

Increased immunoregulatory CD4+CD25+ T cell subset and CTLA-4 expression in cord blood CD4+ T cells may contribute to the increased degree of tolerance following unrelated cord blood versus unrelated adult donor blood stem cell transplantation. Blood 98(11 Part 1): 380a-381a, November 16, 2001

Cytomegalovirus ventriculoencephalitis after unrelated double cord blood stem cell transplantation with an alemtuzumab-containing preparative regimen for Philadelphia-positive acute lymphoblastic leukemia. Journal of Korean Medical Science 25(4): 630-633, 2010

Comparison of unrelated cord blood transplantation and HLA-identical sibling peripheral blood stem cell transplantation for the treatment of adult hematological malignancies. Zhonghua Xue Ye Xue Za Zhi 38(8): 673-679, 2017

High-dose Chemotherapy with Stem Cell Rescue Provided Durable Remission for Classical Hodgkin Lymphoma-type Post-transplant Lymphoproliferative Disorder after Unrelated Cord Blood Transplantation: A Case Report and Review of the Literature. Internal Medicine 56(14): 1873-1877, 2017

Unrelated umbilical cord blood transplantation as salvage treatment for engraftment failure following autologous stem cell transplantation. Leukemia Research 32(7): 1157-1159, 2008

Successful treatment of advanced extranodal NK/T cell lymphoma with unrelated cord blood transplantation. Tohoku Journal of Experimental Medicine 211(4): 395-399, 2007

Adult T-cell leukemia/lymphoma in donor cells responding to second allogeneic hematopoietic stem cell transplantation using unrelated cord blood: the Nagasaki Transplant Group experience. Leukemia & Lymphoma 57(12): 2946-2948, 2016

Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation 18(4): 565-574, 2013

Successful treatment of relapsed blastic natural killer cell lymphoma with unrelated cord blood transplantation. Bone Marrow Transplantation 30(1): 41-44, July 1, 2002